The effect of laparoscopic sleeve gastrectomy in the treatment of polycystic ovary syndrome

doi:10.3877/cma.j.issn.1674-3946.2019.04.033

Abstract

Abstract:

Objective

To investigate the efficacy and safety of laparoscopic sleeve gastrectomy for the treatment of polycystic ovary syndrome, and to provide a feasible new method for the treatment of polycystic ovary syndrome.

Methods

Retrospective analysis of medical history of 13 patients who had polycystic ovary syndrome and underwent laparoscopic sleeve gastrectomy in the People’s Hospital of Xinjiang Uygur Autonomous Region from January 2015 to December 2017 was performed. Telephone follow-up was conducted at the time of 1 month, 3 months, 6 months and 1 year after the surgery, the changes of menstruation, skin, hair, sex hormones and etc were investigated.

Results

No complications occurred in 13 cases. The symptoms of polycystic ovary syndrome were relieved in different degrees after the surgery.

Conclusion

Laparoscopic sleeve gastrectomy is a safe and effective method for the treatment of polycystic ovary syndrome.

Key words: Polycystic ovary syndrome, Laparoscopy, Gastrectomy

Aili Aikebaiero·, Tuhongjiang Airexiatio·, Xiaoyong Liu, Xiuli Deng, Abudureyimu Kelimuo·. The effect of laparoscopic sleeve gastrectomy in the treatment of polycystic ovary syndrome[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2019, 13(04): 424-426.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhpwkssxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3946.2019.04.033

https://zhpwkssxzz.cma-cmc.com.cn/EN/Y2019/V13/I04/424

Figures/Tables 3

References 20

[1]	Dumont A, Robin G, Catteau－Jonard S, et al. Role of Anti－Mullerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review[J]. Reprod Biol Endocrinol, 2015，13：137-137.
[2]	Faghfoori Z, Fazelian S, Shadnoush M, et al. Nutritional management in women with polycystic ovary syndrome: A review study[J]. Diabetes Metab Syndr, 2017，11(Suppl 1)：S429-S432.
[3]	Anwar S, Shikalgar N. Prevention of type 2 diabetes mellitus in polycystic ovary syndrome: A review[J]. Diabetes Metab Syndr, 2017，11(Suppl 2)：S913-S917.
[4]	Riley JK, Jungheim ES. Is there a role for diet in ameliorating the reproductive sequelae associated with chronic low－grade inflammation in polycystic ovary syndrome and obesity？[J]. Fertil Steril, 2016，106(3)：520-527.
[5]	Csenteri OK, Sandor J, Kalina E, et al. The role of hyperinsulinemia as a cardiometabolic risk factor independent of obesity in polycystic ovary syndrome[J]. Gynecol Endocrinol, 2017，33(1)：34-38.
[6]	Chen X, Jia X, Qiao J, et al. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome[J]. J Mol Endocrinol, 2013，50(2)：R21-R37.
[7]	木良善，赵越，乔杰. 肥胖与多囊卵巢综合征的关联性及潜在机制[J]. 中华生殖与避孕杂志，2018，38(4)：343-349.
[8]	Mitka M. Bariatric surgery continues to show benefits for patients with diabetes[J]. JAMA, 2012，307(18)：1901-1902.
[9]	Althuwaini S, Bamehriz F, Aldohayan A, et al. Prevalence and Predictors of Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy[J]. Obes Surg, 2018，28(4)：916-922.
[10]	Li R, Qiao J, Yang D, et al. Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system[J]. Eur J Obstet Gynecol Reprod Biol, 2012，163(2)：165-169.
[11]	Yousseif A, Emmanuel J, Karra E, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl－ghrelin, peptide YY3－36 and active GLP－1 levels in non－diabetic humans[J]. Obes Surg, 2014，24(2)：241-252.
[12]	Andrade VH, Mata AM, Borges RS, et al. Current aspects of polycystic ovary syndrome: A literature review[J]. Rev Assoc Med Bras (1992), 2016，62(9)：867-871.
[13]	Skubleny D, Switzer NJ, Gill RS, et al. The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta－analysis[J]. Obes Surg, 2016，26(1)：169-176.
[14]	Conway G, Dewailly D, Diamanti－Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology[J]. Eur J Endocrinol, 2014，171(4)：P1-P29.
[15]	Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in China: a large community－based study[J]. Hum Reprod, 2013，28(9)：2562-2569.
[16]	彭真，张全，王丽娥，等. 控制体重对肥胖型多囊卵巢综合征患者的疗效观察[J]. 生殖医学杂志，2016，25(11)：992-997.
[17]	Naderpoor N, Shorakae S, Joham A, et al. Obesity and polycystic ovary syndrome[J]. Minerva Endocrinol, 2015，40(1)：37-51.
[18]	Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society[J]. Fertil Steril, 2009，92(6)：1966-1982.
[19]	王恺京，忻颖，周小钢，等. 腹腔镜胃袖状切除对多囊卵巢综合征生殖内分泌功能改善的作用[J]. 中国微创外科杂志，2014，14(10)：942-944.
[20]	Wang K, Jiang Q, Zhi Y, et al. Contrasting Sleeve Gastrectomy with Lifestyle Modification Therapy in the Treatment of Polycystic Ovary Syndrome[J]. J Laparoendosc Adv Surg Tech A, 2015，25(6)：493-498.

病例	年龄(岁)	体重(kg)	卵巢多囊	BMI(kg/m²)	mFG评分	月经周期(d)	LH/FSH	血清睾酮(ng/ml)
1	32	87	无	30.82	4	90	2.22	0.40
2	28	104	有	37.74	6	60	1.62	0.80
3	25	111	无	38.41	4	120	0.45	0.71
4	34	106	无	39.90	2	90	1.84	0.89
5	26	103	有	36.93	7	30	1.44	1.33
6	32	83	无	32.02	5	60	2.23	0.90
7	35	90	无	31.14	8	60	1.20	0.76
8	24	89	无	32.30	3	90	2.23	1.14
9	28	123	无	45.73	6	60	0.63	0.35
10	22	92	有	32.99	2	30	1.75	0.82
11	23	119	无	43.71	2	120	0.56	0.32
12	28	118	有	47.27	4	60	1.68	0.80
13	27	105	无	37.65	6	30	2.30	0.83

病例	年龄(岁)	体重(kg)	卵巢多囊	BMI(kg/m²)	mFG评分	月经周期(d)	LH/FSH	血清睾酮(ng/ml)
1	32	87	无	30.82	4	90	2.22	0.40
2	28	104	有	37.74	6	60	1.62	0.80
3	25	111	无	38.41	4	120	0.45	0.71
4	34	106	无	39.90	2	90	1.84	0.89
5	26	103	有	36.93	7	30	1.44	1.33
6	32	83	无	32.02	5	60	2.23	0.90
7	35	90	无	31.14	8	60	1.20	0.76
8	24	89	无	32.30	3	90	2.23	1.14
9	28	123	无	45.73	6	60	0.63	0.35
10	22	92	有	32.99	2	30	1.75	0.82
11	23	119	无	43.71	2	120	0.56	0.32
12	28	118	有	47.27	4	60	1.68	0.80
13	27	105	无	37.65	6	30	2.30	0.83

Please choose a citation manager

Content to export